乳腺癌雌激素受体mRNA的变异剪切与Tam oxifen耐受

Relationship between Estrogen Receptor Message RNA Variant Splicing in Human Breast Cancer and Tamoxifen Resistance

目的 通过检测不同来源乳腺癌雌激素受体 m RNA水平的正常剪切和变异剪切 ,初步探讨人类乳腺癌 ta-m oxifen耐受和雌激素受体 m RNA变异剪切的关系。方法 利用 RT- PCR技术检测临床正常乳腺、乳腺癌和乳腺癌 ta-m oxifen耐受组织中雌激素受体 m RNA的剪切条带 ,并予以比较。结果 正常乳腺、乳腺癌和乳腺癌 tam oxifen耐受组织中均有雌激素受体 m RNA的正常剪切和变异剪切 ,其中 12 5 0 bp的变异剪切条带最多见 ,但乳腺癌 tam oxifen耐受组织中的变异剪切条带较多 ,而乳腺癌 MCF- 7细胞系不存在变异剪切。结论 tam oxifen长期作用于乳腺癌组织可导致雌激素受体 m

Objective To compare the difference of estrogen receptor variant splicing in different human breast cancer tissues and discuss the relationship between the tamoxifen resistance and estrogen receptor variant splicing. Methods The different strips of estrogen receptor mRNA from normal human breast tissues, human breast cancer tissues and tamoxifen-resistance breast cancer tissues were detected by the RT-PCR methods. Results There were both normal splicing and variant splicing strips wherever in normal breast tissues, breast cancer tissues and tamoxifen-resistance breast cancer tissues. A variant splicing strip of 1250 bp was most present. But there was no variant splicing strip in MCF-7 breast cancer cells. Conclusion Long-time effect of tamoxifen could result in frequently variant splicing in breast cancer tissues and affect the function of the normal estrogen receptors.